CCCC logo

C4 Therapeutics (CCCC)

Profile

Full Name

C4 Therapeutics, Inc.

Ticker Symbol

CCCC

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

October 2, 2020

Indexes

Not included

Website

http://www.c4therapeutics.com

Employees

110

Key Details

Price

$1.19(-3.25%)

Market cap

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$35.58M(+71.44% YoY)

Annual EPS

-$1.52(+43.07% YoY)

PE ratio

-

Next earnings date

May 8, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$1.19
CCCC price is $1.19

30-Day Relative Volume

1.23
CCCC 30-day relative volume is 1.23

Price Performance

Price Most recent change

-3.25%
CCCC price was down -3.25% on Apr 15, 2025

Price YTD change

-66.94%
CCCC price is down -66.94% since January 1st

Price 1-year change

-82.65%
CCCC price is down -82.65% year-on-year

Price 3-year change

-86.7%
CCCC price is down -86.7% over the past 3 years

Price Range

Price All-time high

$51.21
CCCC price is currently -97.68% below its historical high of $51.21

Price 3-year low

$1.06
CCCC price is currently +12.26% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$84.48M
CCCC market capitalization is $84.48 million

Market cap 3-year change

-80.64%
CCCC market capitalization is down -80.64% over the past 3 years

Market cap All-time high

$2.45B
CCCC market capitalization is currently -96.55% below its historical high of $2.45 billion

Market cap sector rank

46.38%
CCCC market capitalization is higher than 46.38% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+3.21%
CCCC shares outstanding is up +3.21% year-on-year

Shares Outstanding 3-Year Change

+45.62%
CCCC shares outstanding is up +45.62% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

1.66
CCCC beta is 1.66

200-day SMA

$4.51
CCCC price is currently -73.59% below its 200-day simple moving average

50-day SMA

$2.30
CCCC price is currently -48.22% below its 50-day simple moving average

RSI

25.36
CCCC 14-day relative strength index is 25.36

Volume

1.23
CCCC 30-day relative volume is 1.23

ATR

$0.15
CCCC average true range is $0.15

10-day Historical Volatility

97.30%
CCCC 10-day historical volatility is 97.30%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$35.58M
CCCC annual revenue is $35.58 million

Revenue Analysts estimate

$24.18M
CCCC annual revenue is currently +47.16% higher than the consensus analysts' forecast

Revenue 1-year change

+71.44%
CCCC annual revenue is up +71.44% year-on-year

Revenue Sector rank

42.33%
CCCC annual revenue is higher than 42.33% of companies in Healthcare sector

EPS

EPS

-$1.52
CCCC annual earnings per share is -$1.52

EPS Analysts estimate

-$1.64
CCCC annual earnings per share is currently -7.41% lower than the consensus analysts' forecast

EPS 1-year change

+43.07%
CCCC annual earnings per share is up +43.07% year-on-year

EPS Sector rank

45.49%
CCCC annual earnings per share is higher than 45.49% of companies in Healthcare sector

Profit

Gross profit

-
CCCC annual gross profit value is unknown

Gross margin

-
CCCC annual gross profit margin value is unknown

Operating profit

-$117.18M
CCCC annual operating income is -$117.18 million

Operating margin

-329.30%
CCCC annual operating profit margin is -329.30%

Net income

-$105.32M
CCCC annual net profit is -$105.32 million

Net margin

-295.96%
CCCC annual net profit margin is -295.96%

Expenses

Total expenses

$152.76M
CCCC annual total expenses is $152.76 million

Operating expenses

$152.76M
CCCC annual total operating expenses is $152.76 million

Cost of goods sold

-
CCCC annual cost of goods sold value is unknown

Selling, general & administrative expenses

$42.12M
CCCC annual SGA is $42.12 million

Depreciation and amortization

$1.82M
CCCC annual depreciation & amortization is $1.82 million

Interest expense

$0.00
CCCC annual interest expense is $0.00

Income tax

$131.00K
CCCC annual income tax is $131.00 thousand

EBIT & EBITDA

EBIT

-$105.19M
CCCC annual earnings before interest & taxes is -$105.19 million

EBITDA

-$103.37M
CCCC annual EBITDA is -$103.37 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$349.60M
CCCC annual total assets is $349.60 million

Non current assets

$91.83M
CCCC annual long term assets is $91.83 million

Current assets

$257.77M
CCCC annual total current assets is $257.77 million

Cash and cash equivalents

$55.50M
CCCC annual cash & cash equivalents is $55.50 million

Accounts receivable

$3.10M
CCCC annual accounts receivable is $3.10 million

Inventory

-
CCCC annual inventory value is unknown

Liabilities

Total liabilities

$133.62M
CCCC annual total liabilities is $133.62 million

Long term liabilities

$88.44M
CCCC annual total long term liabilities is $88.44 million

Current liabilities

$45.18M
CCCC annual total current liabilities is $45.18 million

Accounts payable

$1.33M
CCCC annual accounts payable is $1.33 million

Debt

Total debt

$65.76M
CCCC annual total debt is $65.76 million

Total debt 1-year change

-7.35%
CCCC annual total debt is down -7.35% year-on-year

Long term debt

$59.98M
CCCC annual long term debt is $59.98 million

Short term debt

$5.77M
CCCC annual short term debt is $5.77 million

Equity & Capital

Shareholders equity

$215.99M
CCCC annual stockholders equity is $215.99 million

Book value

$215.99M
CCCC annual book value is $215.99 million

Retained earnings

-$633.70M
CCCC annual retained earnings is -$633.70 million

Working capital

$212.59M
CCCC annual working capital is $212.59 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$65.16M
CCCC annual cash flow from operations is -$65.16 million

Cash from operations 1-year change

+39.01%
CCCC annual cash flow from operations is up +39.01% year-on-year

Cash from investing

-$51.27M
CCCC annual cash flow from investing activities is -$51.27 million

Cash from investing 1-year change

-132.38%
CCCC annual cash flow from investing activities is down -132.38% year-on-year

Cash from financing

$45.34M
CCCC annual cash flow from financing activities is $45.34 million

Cash from financing 1-year change

-0.34%
CCCC annual cash flow from financing activities is down -0.34% year-on-year

CAPEX

CAPEX

$180.00K
CCCC annual capital expenditures is $180.00 thousand

CAPEX 1-year change

-89.46%
CCCC annual capital expenditures is down -89.46% year-on-year

Free Cash Flow

Free cash flow

-$65.34M
CCCC annual free cash flow is -$65.34 million

Free cash flow 1-year change

+39.81%
CCCC annual free cash flow is up +39.81% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

-
CCCC annual gross profit margin value is unknown

Operating margin

-329.30%
CCCC annual operating profit margin is -329.30%

Net margin

-295.96%
CCCC annual net profit margin is -295.96%

ROA & ROE

ROA

-29.01%
CCCC annual return on assets is -29.01%

ROE

-45.58%
CCCC annual return on equity is -45.58%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
CCCC price to earnings ratio value is unknown

PE ratio Sector rank

-
CCCC price to earnings ratio is unknown

PB Ratio

PB ratio

0.39
CCCC price to book ratio is 0.39

PB ratio Sector rank

26.42%
CCCC price to book ratio is higher than 26.42% of companies in Healthcare sector

PS Ratio

PS ratio

2.37
CCCC price to sales ratio is 2.37

PS ratio Sector rank

46.15%
CCCC price to sales ratio is higher than 46.15% of companies in Healthcare sector

Enterprise value

Enterprise value

$94.73M
CCCC enterprise value is $94.73 million

Enterprise value Sector rank

49.67%
CCCC enterprise value is higher than 49.67% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-0.92
CCCC EV/EBITDA is -0.92

EV/EBITDA Sector rank

44.35%
CCCC EV/EBITDA is higher than 44.35% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

5.71
CCCC annual current ratio is 5.71

Quick ratio

-
CCCC annual quick ratio value is unknown

Leverage

Debt to equity

0.00
CCCC annual debt to equity ratio is 0.00

Interest coverage ratio

-
CCCC annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

-
CCCC piotroski f-score value is unknown

Altman Z-Score

-2.32
CCCC altman z-score is -2.32

Analyst ratings

Recent major analysts updates

Dec 19, 24 Wells Fargo
Overweight
Nov 18, 24 Stephens & Co.
Equal-Weight
Aug 6, 24 BMO Capital
Outperform
May 9, 24 Wells Fargo
Equal-Weight
May 9, 24 Stifel
Buy
Feb 26, 24 Morgan Stanley
Equal-Weight
Feb 23, 24 Stifel
Buy
Jan 29, 24 JP Morgan
Neutral
Dec 13, 23 Stifel
Buy
Nov 6, 23 Morgan Stanley
Equal-Weight

Institutional Ownership

Similar stocks

Lexeo Therapeutics (LXEO)
SY logo
So-Young International (SY)
GALT logo
Galectin Therapeutics (GALT)
OCX logo
OncoCyte (OCX)
CRVO logo
CervoMed (CRVO)
BDSX logo
Biodesix (BDSX)
KYTX logo
Kyverna Therapeutics (KYTX)
SRZN logo
Surrozen (SRZN)
QIPT logo
Quipt Home Medical (QIPT)
  • What is the ticker symbol for C4 Therapeutics?
  • Does C4 Therapeutics pay dividends?
  • What sector is C4 Therapeutics in?
  • What industry is C4 Therapeutics in?
  • What country is C4 Therapeutics based in?
  • When did C4 Therapeutics go public?
  • Is C4 Therapeutics in the S&P 500?
  • Is C4 Therapeutics in the NASDAQ 100?
  • Is C4 Therapeutics in the Dow Jones?
  • When was C4 Therapeutics's last earnings report?
  • When does C4 Therapeutics report earnings?
  • Should I buy C4 Therapeutics stock now?

What is the ticker symbol for C4 Therapeutics?

The ticker symbol for C4 Therapeutics is NASDAQ:CCCC

Does C4 Therapeutics pay dividends?

No, C4 Therapeutics does not pay dividends

What sector is C4 Therapeutics in?

C4 Therapeutics is in the Healthcare sector

What industry is C4 Therapeutics in?

C4 Therapeutics is in the Biotechnology industry

What country is C4 Therapeutics based in?

C4 Therapeutics is headquartered in United States

When did C4 Therapeutics go public?

C4 Therapeutics's initial public offering (IPO) was on October 2, 2020

Is C4 Therapeutics in the S&P 500?

No, C4 Therapeutics is not included in the S&P 500 index

Is C4 Therapeutics in the NASDAQ 100?

No, C4 Therapeutics is not included in the NASDAQ 100 index

Is C4 Therapeutics in the Dow Jones?

No, C4 Therapeutics is not included in the Dow Jones index

When was C4 Therapeutics's last earnings report?

C4 Therapeutics's most recent earnings report was on Feb 27, 2025

When does C4 Therapeutics report earnings?

The next expected earnings date for C4 Therapeutics is May 8, 2025

Should I buy C4 Therapeutics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page